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WOMEN’S HEAlTH
Menopause reflects a change in the woman’s physiological 
hormonal status and is regarded as 
a pivotal point in a woman’s life. The 
commonest symptoms experienced 
by women during the menopause are 
hot flushes and night sweats. Although 
HRT remains the gold standard for the 
treatment of menopausal symptoms, 
certain controversial studies have led 
to a shift against the regular use of 
HRT. Many physicians and women 
have turned to alternative ‘natural’ 
products, hoping that these can 
substitute the need for HRT. The 
evidence base for the efficacy and 
safety of phytoestrogens, in particular 
isoflavones, will be discussed.
Introduction
Menopause reflects a change in 
the woman’s physiological hormonal 
status, and although not equivalent to 
an illness, it is regarded as a pivotal 
point in a woman’s life. Its management 
should not be neglected because while 
some women may go through it without 
noticing, it is generally accompanied 
by a variety of disorders. Top of the 
list in 40% to 80% of Western women 
are hot flushes and night sweats 
which can result in decreased quality 
of life.¹ Increased public expectations 
and awareness of health issues have 
contributed to an increased demand 
for products related to menopausal 
symptoms.
The gold standard for the treatment 
of menopausal symptoms is the 
conventional HRT that actually corrects 
the underlying lack of female hormones. 
Results of major RCTs including 
the Women Health Initiative2, Heart 
Estrogen/Progestin Replacement Study 
II³ and the large British observational 
study the Million Women Study4 have 
demonstrated an increased risk of 
cardiovascular disease and cancer of 
the breast with HRT use. Following 
these controversial studies over 90% 
of family physicians in Malta  have 
changed their prescribing habits of 
HRT.5 Due to the fear of these adverse 
effects and possible long-term risks 
of HRT, many women are reluctant to 
use HRT and have turned to alternative 
‘natural’ products hoping that these can 
substitute the need for HRT.
A number of epidemiological studies 
suggest that the female populations 
in Asian nations like Japan, China and 
South-east Asia, are less burdened 
by menopausal symptoms than those 
of Western countries. It has been 
postulated that these differences may 
be due to the traditional Asian diet 
that is rich in Soy, which contains 
substances that are structurally similar 
to estrogen and bind to ER and hence 
have been called phytoestrogens. 
Since their binding affinity to ER is 
preferential, i.e. stronger binding affinity 
to ERβ than to ERα, they are better 
classified as SERMs. 
Media coverage has led to an 
increased consumer awareness of soy, 
which has resulted in skyrocketing 
sales of soy products and supplements. 
Many advertising campaigns have 
specifically targeted females and 
depicted soy and other phytoestrogens 
as the alternative to conventional 
HRT for menopausal symptoms 
with the added benefits of possible 
protective properties against breast 
cancer and heart disease. These 
products are classified under CAM 
and not as medicinals. Although they 
are freely available in health shops 
and pharmacies as over-the-counter 
products, many women request 
information and advice from their GP 
and other health practitioners about the 
effectiveness, safety and tolerability of 
these products before purchase.
What is the evidence base to support 
the effectiveness of phytoestrogen 
therapy in menopausal women for 
the control of hot flushes?  
CAM products tend to lack a 
research tradition and infrastructure, 
since funding is generally limited 
compared with the amount spent 
by the pharmaceutical industry on 
conventional drugs. However over 
the past 10 years several studies 
both of experimental animal type and 
clinical trials have been carried out 
to test the efficacy and tolerability of 
phytoestrogens derived from both Soy 
and Red Clover.
 It is therefore important that 
proper recommendations are based 
on appropriate and good quality 
evidence. EBM or EBP aims to apply 
the best available evidence gained 
from the scientific method to clinical 
decision making. The strongest 
evidence quality is derived 
from systematic reviews of 
double/triple blind RCT 
followed by that of 
individual properly 
designed RCTs.
The evidence 
base from 
systematic 
reviews of studies 
about efficacy of 
phytoestrogens 
is sometimes 
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conflicting. Several reviews have 
evaluated the clinical evidence relating 
isoflavone treatment to the relief of 
menopausal hot flash symptoms. The 
majority of these reviews included a 
variety of isoflavone sources, often 
without differentiating between the 
identities of individual isoflavones 
contained in the study product. Hence 
reports concluding that isoflavone 
supplements do not significantly reduce 
hot flash symptoms may be incorrect. 
The lack of differentiation  between 
individual isoflavones contained in 
heterogeneous isoflavone mixtures from 
differing sources can be misleading 
when designing studies, interpreting 
results, and conducting reviews.
One critical review conducted 
by Williamson-Hughes et al.6 has 
demonstrated that a statistically 
significant reduction of hot flushes is 
achieved only in those studies which 
provided more than 15mg genistein 
(type of isoflavone). Another review by 
Bolanos et al7 analyzed 19 RCTs and 
demonstrated an overall significant 
reduction in hot flushes with soy 
preparations. The systematic review 
and meta-analysis conducted by 
Taku et al8 also concluded that soy 
isoflavone supplements, derived by 
extraction or chemical synthesis, 
are significantly more effective than 
placebo in reducing the frequency and 
severity of hot flushes.
As described, several double-
blinded RCTs with particular 
standardised formulations of 
isoflavones have demonstrated 
positive effects in controlling hot 
flushes.6,7,8,9 The strongest evidence is 
for formulations containing specifically 
genistein.6,10 It was also suggested that 
genistein may have a favourable effect 
on some cardiovascular markers.11 This 
positive effect of genistein without any 
adverse effects on the endometrium 
and vagina after 1 year treatment were 
also demonstrated by another RCT.12 
The safety concerns of isoflavones 
were also addressed in another RCT 
with no effects on the endometrium and 
the breast, demonstrated by biopsy 
specimens.13
Less evidence exists to address 
the effects of soy isoflavones on bone 
metabolism in postmenopausal women 
and their place in the prevention 
and treatment of postmenopausal 
osteoporosis. In vitro and animal 
studies have shown that they act in 
multiple ways to exert their bone-
supporting effects by acting on 
both osteoblasts and osteoclasts. 
Epidemiological studies and clinical 
trials suggest that soy isoflavones 
have beneficial effects on bone mineral 
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density, bone turnover markers, 
and bone mechanical strength in 
postmenopausal women.14
The North America Menopause 
Society in 2010 published a report 
stating that Soy-based isoflavones 
are modestly effective in relieving 
menopausal symptoms and 
supplements providing higher 
proportions of genistein (type of 
isoflavone) or increased S-equol 
content (isoflavan, metabolite of the 
soy isoflavonedaidzein) may provide 
more benefits. However larger studiesin 
younger postmenopausal women, and 
more research is needed to understand 
the modes of use of soy isoflavone 
supplements in women.15
Conclusion
There is enough evidence to 
support the use of isoflavones 
especially genistein, in the treatment 
of acute menopausal symptoms. 
Different sources and supplements of 
phytoestrogens are available on the 
market however many of them lack 
standardization of the content of the 
active ingredient which can seriously 
affect the bioavailability. Counseling of 
women regarding which preparations 
are most suitable and to avoid 
unrealistic expectations from these 
preparations is very important. 
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